InvestorsHub Logo
Followers 861
Posts 28265
Boards Moderated 1
Alias Born 03/16/2014

Re: None

Thursday, 09/20/2018 8:38:26 PM

Thursday, September 20, 2018 8:38:26 PM

Post# of 30141
In the meantime, I have a few minutes to spare, so I will quickly mention a few of the important facts about the DEA’s imminent rescheduling of CBD that are important to know in order to understand all aspects of this historic event

Epidiolex is a medication manufactured by GW Pharma —not J&J, Merck or P&G — this is their very first FDA-approved medication so they do not currently sell any other medications in America — they are a small player in the overall pharmaceutical scene, specializing in developing medications derived from MJ — they are not “big pharma”

Epidiolex is MJ-derived CBD

Epidiolex is NOT Hemp-derived CBD

Epidiolex was approved by the FDA for only 2 very specific medical indications — the treatment of seizures in Dravet and Lennox-Gastaut Syndromes — which means those are the only patients approved to receive Epidiolex

The DEA has to reschedule Epidiolex, which means that the federal government is acknowledging the medical value of a constituent of MJ for the very first time in history

The vast majority of people closely following this process believe that the FDA will also reschedule more generally CBD

Gotta run for now... to be continued


Sleek

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.